A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in
Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort followin
| Condition(s) | Idiopathic Nephrotic Syndrome |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. This absence of structured follow up makes it difficult to set up prospective studies. The main objective is to create a prospective cohort of pediatric INS patients to collect cases treated in SNP centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials. |
| Who can participate | Inclusion Criteria: * Patient under 18 years of age * With idiopathic nephrotic syndrome (according to SPN criteria) beginning after January 1, 2018 * Child seen at least once in consultation or hospitalization by a pediatrician member of the Society of Pediatric Nephrology * Residing in France * Consent signed by parents and patient's agreement to participate (if of age) * Affiliated to a social security system. Exclusion Criteria: * Refusal of the patient or legal representatives to participate in the cohort |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Hospital, Limoges |
| Locations | Agen, France; Amiens, France; Auxerre, France; Bayonne, France; Besançon, France; Bordeaux, France (+42 more sites) |
| Start date | 2020-03-13 |
| NCT ID | NCT04207580 |
| Official listing | https://clinicaltrials.gov/study/NCT04207580 |